← All trials
NCT03143218
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 17, 2017
- Primary completion
- Jan 15, 2020
- Completion date
- Jun 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 6000
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of LondonLead sponsor
- University of LondonReponsible party - principal investigator
- Malaria Research and Training Center, Bamako, MaliCollaborator
- Institut et Haute école de la Santé, La SourceCollaborator
- Malaria Research and Training Center, Bamako, MaliOverall official - principal investigator
- Malaria Research and Training Center, Bamako, MaliStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.